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Abstract Endoglin is a component of the transforming growth
factor L (TGF-L) receptor complex, highly expressed by
endothelial cells. Mutations in the endoglin gene are responsible
for hereditary hemorrhagic telangiectasia type 1 (HHT1), an
autosomal dominant vascular disorder caused by a haploinsuffi-
ciency mechanism. Vascular lesions (telangiectasia and arter-
iovenous malformations) in HHT1 are associated with loss of the
capillary network, suggesting the involvement of endoglin in
vascular repair processes. Using the chick chorioallantoic
membrane (CAM) as an angiogenic model, we have analyzed
the expression and function of chicken endoglin. A pan-specific
polyclonal antibody (pAb) recognized chicken endoglin as
demonstrated by immunostaining and Western blot analysis. In
ovo treatment of chicken embryos with this pAb resulted in a
significantly increased area of CAM. This effect was likely
mediated by modulation of the ligand binding to endoglin as this
pAb was able to inhibit TGF-L1 binding. These results support
the involvement of endoglin in the angiogenic process.
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1. Introduction
Endoglin is a component of the transforming growth factor
L (TGF-L) receptor system able to modulate cellular responses
to TGF-L [1^3]. Endoglin is a 180 kDa homodimeric mem-
brane glycoprotein which binds at least TGF-L1, TGF-L3,
activin-A, and BMP-7 [4^6]. This ligand binding requires
the expression of signaling receptors [5,7], which form hetero-
meric complexes with endoglin [3,5,8]. To date, endoglin has
been found to be highly expressed on endothelial cells of
human [9], pig [8], and mouse [10] origin, but little is known
about endoglin expression in the chicken. The high expression
levels of endoglin in endothelial cells seem to be critical for the
vascular physiology as mutations in the endoglin gene are
responsible for hereditary hemorrhagic telangiectasia type 1
(HHT1), a dominant vascular disorder associated with fre-
quent epistaxis, telangiectases, gastrointestinal bleedings, and
arteriovenous malformations in brain, lung and liver [11^13].
It has been postulated that HHT1 is originated by a mecha-
nism of endoglin haploinsu⁄ciency [12^14]. This ¢nding, to-
gether with the localized loss of capillaries found in the HHT
lesions, suggests that endoglin might be involved in angiogenic
repair processes. This hypothesis would be compatible with
the crucial role that TGF-L plays in vascular development
and remodeling [15]. Recently, Li et al. [16] have reported
that mice lacking endoglin die at gestational day 11.5 with
poor vascular smooth muscle development and arrested endo-
thelial remodeling. In the current study we have identi¢ed
chicken endoglin using a speci¢c polyclonal antibody (pAb)
and demonstrated that antibodies to endoglin are able to
modulate the angiogenic process of the chick chorioallantoic
membrane (CAM) in developing chicken embryos.
2. Materials and methods
2.1. Antibodies
The anti-endoglin pAb was obtained by infection of New Zealand
rabbits with a recombinant vaccinia virus expressing human endoglin
[17]. As a negative control, antisera from animals infected with a
recombinant thymidine kinase-de¢cient vaccinia virus (anti-TK3)
were used. Rabbit immunoglobulins were puri¢ed from sera by a⁄n-
ity chromatography using protein G Sepharose (Pharmacia Fine
Chemicals, Uppsala, Sweden). The mouse monclonal antibody
(mAb) 44G4 (anti-endoglin) has been previously described [9].
2.2. Immunohistochemistry
Lung tissue sections were obtained by surgical procedures from
White Leghorn adult chickens (Farm Rodr|¤guez-Serrano, Salamanca,
Spain). Tissue sections were ¢xed by immersion in 4% bu¡ered for-
malin during 24 h. After dehydration, pieces were embedded in par-
a⁄n and 3 Wm sections were cut and mounted on glass slides and
stained with the rabbit pAb anti-endoglin. The presence of endoglin
was revealed using an avidin-biotin-complex immunoperoxidase meth-
od (ABC Staining System, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) that uses 3,3P-diaminobenzidine (DAB) as a substrate.
Samples were counterstained with hematoxylin. For CAM immuno-
staining, egg shells were excised and CAM were removed, ¢xed over-
night in 4% paraformaldehyde in 0.1 M phosphate bu¡er, pH 7.1,
washed three times with phosphate bu¡ered saline (PBS) and permea-
bilized with 1% Triton X-100 in PBS for 4 h. Membranes were then
incubated with the rabbit pAb to endoglin, followed by a FITC-la-
beled anti-rabbit Ig. Endoglin labeling was revealed by £uorescence
microscopy using a confocal scanner laser (MRC1024; Bio-Rad Lab-
oratories, Hercules, CA, USA) mounted on a Zeiss Axiovert 135
microscope (Zeiss, Oberkochen, Germany).
2.3. Angiogenic assays in ovo
Fertilized White Leghorn eggs were incubated at 38.2‡C and 60^
90% relative humidity for 36 h, corresponding to stage HH8^HH10 of
embryonic development [18]. After this period of time, windows were
made in the shells and indicated treatments were applied directly over
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 2 5 2 - 1
*Corresponding author. Fax: (34) (91) 5627518.
E-mail: bernabeu.c@cib.csic.es
1 Present address: Institut fu«r Medizinische Mikrobiologie und Hy-
giene, Universita«t Regensburg, D-93053 Regensburg, Germany.
Abbreviations: CAM, chick chorioallantoic membrane; DAB, 3,3P-
diaminobenzidine; HHT, hereditary hemorrhagic telangiectasia;
mAb, monoclonal antibody; pAb, polyclonal antibody; PAGE, poly-
acrylamide gel electrophoresis; TGF-L, transforming growth factor L
FEBS 22692 30-9-99 Cyaan Magenta Geel Zwart
FEBS 22692 FEBS Letters 459 (1999) 249^254
the embryos. All treatments were assessed in a ¢nal volume of 200 Wl
obtained by mixing equal volumes of stimuli and 1.4% methylcellulose
(Serva) in PBS. Assays involving antibodies and TGF-L were carried
out with either 50 Wg of puri¢ed immunoglobulins and/or 25 ng of
TGF-L (RpD Systems, Abingdon, UK) per embryo. These amounts
were selected as optimal from a dose dependence curve. After addition
of stimuli, eggs were sealed with cellotape and incubated for an addi-
tional period of 24 h. Then, egg shells were excised, the CAM were
Fig. 1. Endoglin expression in the chicken lung vasculature. Lung tissue sections were stained with a pAb anti-endoglin using an indirect immu-
noperoxidase method. Endoglin is present in the vessels as evidenced by the brown staining of the peroxidase reaction. Samples were counter-
stained with hematoxylin. Panel A shows expression of endoglin at the lumen of a small artery (magni¢cation U417). Arrowheads in panel B
indicate expression of endoglin at the endothelial cell monolayer of an artery wall (magni¢cation U1038).
C
Fig. 2. Expression of endoglin in CAM. A,B: Immunostaining of CAM. Eggs with embryos were incubated for 2 days, shells were excised and
CAM were removed, ¢xed, and permeabilized. Membranes were incubated with either the rabbit pAb to endoglin (A), or the anti-TK3 pAb as
a negative control (B), followed by a FITC-labeled anti-rabbit Ig. Samples were analyzed by confocal microscopy. Views of a total of 16 se-
quential layers at 3.6 Wm intervals were collected, digitized and computerized to yield a three-dimensional composition. Fluorescein labeling re-
veals that endoglin is present in the branching capillary network (A). Magni¢cation U100. C: Biochemical characterization of chicken endoglin.
CAM from embryos corresponding to 40 h were lysed and soluble extracts were electrophoresed on a 6% polyacrylamide gel under non-reduc-
ing conditions. After electrophoresis, samples were transferred to nitrocellulose and speci¢c immunodetection was carried out by incubation
with speci¢c anti-endoglin or anti-TK3 (negative control) puri¢ed immunoglobulins. The polypeptide corresponding to chick endoglin, indicated
by an arrow, was visualized using a chemiluminescence assay.
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removed and ¢xed on 4% paraformaldehyde bu¡ered in 0.1 M phos-
phate bu¡er, pH 7.1. After ¢xation, membranes were washed three
times with PBS and permeabilized with 1% Triton X-100 in PBS for
4 h. Finally, membranes were stained with DAB, making use of the
endogenous peroxidase, and photographed. Quantitative measure-
ments of the CAM areas were performed with a ruled square mask
under a binocular lens estimating horizontal diameters between CAM
growth edges. Areas were calculated assuming a circular shape of the
CAM. Results showing CAM growth were plotted as cumulative per-
centage of embryos with equal or larger areas compared to their
corresponding values. A total of nine experiments were carried out
and on average, 10 embryos were tested for each treatment, discarding
non-viable embryos.
2.4. Western blot analysis
Isolated embryos corresponding to 2 days of development were
excised and minced in PBS containing a protease inhibitor cocktail
with a glass potter in microcentrifuge plastic tubes. Approximately
500 mg of wet crude tissue was used as starting material, and all
manipulations were carried out at 4‡C. After mincing, non-disrupted
tissues were discarded by spinning down at 600Ug for 10 min. Dis-
rupted materials were pelleted and washed twice by centrifugation at
20 000Ug for 30 min and ¢nally resuspended at 1.5 mg/ml of total
protein concentration (recovery as wet weight was estimated as 10%
of the starting material) for 20 h in solubilization bu¡er (2% Triton X-
100, 10 mM Tris, 150 M NaCl, 1 mM EDTA pH 7.4, and a protease
inhibitor cocktail). After solubilization, samples were centrifuged as
described above and soluble fractions were used in Western blot anal-
ysis. For this purpose, equal amounts of total protein were subjected
to SDS-PAGE on 6% polyacrylamide gels under non-reducing con-
ditions. Proteins were electrophoretically transferred to nitrocellulose
membranes (Millipore Corp., Bedford, MA, USA). Filters were
blocked with PBS containing 5% milk powder for 1 h. Speci¢c im-
munodetection was carried out by incubation overnight at room tem-
perature with anti-endoglin or anti-TK3 rabbit pAb, followed by
peroxidase-conjugated goat anti-rabbit Ig. The presence of endoglin
was revealed using a chemiluminescence assay (ECL detection kit,
Amersham Ibe¤rica, Madrid, Spain).
2.5. Receptor a⁄nity labeling
For a⁄nity labeling, 5U106 stable transfectants of rat myoblasts
overexpressing human endoglin [7] were subjected to speci¢c a⁄nity
labeling with 50 pM of [125I]TGF-L1 (speci¢c activity 1200^2000Ci/
mmol; Amersham Ibe¤rica) for 4 h in the absence or presence of 5^50
Wg of puri¢ed anti-endoglin or anti-TK3 immunoglobulins in HEPES
bu¡er containing 0.1% bovine serum albumin. After a⁄nity labeling,
cells were washed and radiolabeled TGF-L1 was cross-linked to spe-
ci¢c cellular receptors with 0.30 mM disuccinimidyl suberate (Pierce
Chemical Co., Rockville, IL, USA) in HEPES bu¡er for 15 min at
4‡C. After chemical cross-linking cell monolayers were washed three
times with HEPES bu¡er. Then, cells were detached by scraping and
soluble extracts were obtained by incubation with lysis bu¡er (1%
Triton X-100, 10 mM Tris, 150 mM NaCl, 1 mM EDTA, and a
protease inhibitor cocktail) for 1 h at 4‡C. Soluble extracts were sub-
jected to speci¢c immunoprecipitation with mAb 44G4 (anti-endoglin)
and SDS-PAGE. Detection of the 125I-labeled endoglin was revealed
with a PhosphorImager 410A and ImageQuant software (Molecular
Dynamics).
Fig. 3. E¡ects of anti-endoglin antibodies or TGF-L1 on CAM development. A: Analysis of CAM vascularization. CAM were excised, ¢xed,
permeabilized and stained with DAB in the presence of hydrogen peroxide. Endogenous peroxidase activity catalyzes precipitation of oxidized
substrate, rendering staining of blood vessels with a brown color. The ratio of blood vessels/area is not altered by treatments, but the total
area of CAM is larger in embryos treated with anti-endoglin antibodies or TGF-L1 as compared with controls (PBS or anti-TK3 antibodies).
B,C: Quantitation of CAM growth. The number of cumulative embryos, expressed as percentage, showing an area scoring equal to or higher
than the x-axis value was plotted. The area corresponding to the y-axis value of 50% represents the median of the distribution. Panel B repre-
sents data from embryos treated with anti-endoglin or anti-TK- antibodies, as indicated. Panel C represents data from embryos treated with
PBS, TGF-L1, or anti-endoglin pAb, as indicated.
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3. Results
3.1. Expression of endoglin in the chicken vasculature
Mammalian endothelial cells express high levels of endoglin
[8^10]. Thus, we analyzed whether endoglin was expressed in
the chicken vasculature using a rabbit pAb to human endoglin
[17]. First, a section of adult chicken lung was stained with the
pAb anti-endoglin. As shown in Fig. 1A, the pAb speci¢cally
recognized the endothelium of a large pulmonary artery, being
unreactive with its tunica media. At a higher magni¢cation,
the expression of endoglin was clearly located in the endothe-
lial cell monolayer of the vessels (Fig. 1B). Next, anti-endoglin
antibodies were used to stain the chicken CAM. As evidenced
by the immuno£uorescence assay of Fig. 2A, the capillary
network was also recognized by the anti-endoglin antibodies.
As expected, a control pAb (anti-TK3) was unreactive with
the CAM vessels (Fig. 2B). Furthermore, we analyzed the
molecular weight of the chicken antigen cross-reactive with
the pAb. Total extracts from CAM were analyzed by Western
blot under non-reducing conditions (Fig. 2C). A speci¢c band
with an apparent molecular weight of 160 kDa corresponding
to the dimeric form of endoglin was detected, in agreement
with a recent report [19]. Taken together, the tissue distribu-
tion and biochemical analyses indicate that endoglin is ex-
pressed on the chicken vasculature.
3.2. Involvement of endoglin in the angiogenic process
Endoglin has been described as an endothelial marker of
neovascularization in humans [20]. To determine whether en-
doglin has an active role in angiogenesis, we used the well
established chicken CAM in vivo model [21]. Basically, eggs
containing developing embryos are injected with the test re-
agents, incubated, and vascularization of the CAM is deter-
mined. We examined the e¡ect of anti-endoglin antibodies on
CAM from young embryos (approximately 40 h), a stage
marked by active neovascularization. Fig. 3A shows represen-
tative CAM subjected to di¡erent treatments, the ratio of
blood vessels/area not being altered by the treatments. Quan-
titative analysis of these experiments revealed that the total
area of CAM was larger in embryos treated with anti-endo-
glin antibodies than that of control samples treated with anti-
TK3 antibodies (Fig. 3B). This increase was similar to that
found in the presence of TGF-L1, included as a positive con-
trol (Fig. 3C). On the other hand, simultaneous addition of
anti-endoglin antibodies and TGF-L1 did not result in an
additive e¡ect. These results suggest an important role of en-
doglin in the angiogenic process.
As TGF-L plays an important role in vascular development
and remodeling [15], and endoglin is a component of the
TGF-L receptor complex, we sought to assess whether the
anti-endoglin pAb used was able to a¡ect ligand binding to
endoglin. TGF-L1 binding of cell transfectants overexpressing
endoglin was analyzed by a⁄nity labeling followed by cross-
linking. Fig. 4 shows that a band of approximately 200 kDa,
corresponding to the endoglin dimer, and the putative TGF-L
receptor types I and II were speci¢cally immunoprecipitated.
Addition of the pAb to the a⁄nity labeling assay prevented
endoglin from binding ligand, whereas control IgG had no
signi¢cant e¡ect. This ¢nding indicates that the pAb to endo-
glin is able to modulate ligand binding to endoglin.
4. Discussion
Endoglin has been cloned and sequenced in human [22,23],
pig [8], and mouse [10,24], but the chicken endoglin sequence
is not available yet. To the best of our knowledge, the only
report about chicken endoglin describes its expression during
heart development using a speci¢c mAb [19]. Thus, during the
formation of the primitive heart tube, endoglin is found at
relatively high levels in both presumptive myocardium and
endocardium; and when myocardium di¡erentiates and devel-
opment proceeds, endoglin expression is progressively re-
duced. However, little is known about endoglin expression
in the endothelium of normal vessels. Here, we demonstrate
the presence of chicken endoglin in the vasculature by immu-
nohistochemical staining and Western blot analyses. The con-
served expression from mammals to birds suggests an impor-
tant function for endoglin in the vascular physiology. We
demonstrate that antibodies to endoglin are able to modulate
the angiogenic process in vivo, indicating an active role for
endoglin in the neovascularization. This conclusion fully
agrees with immunohistological data from three di¡erent
types of pathologies. First, vascular lesions (telangiectasia
and arteriovenous malformations) in endoglin haploinsu⁄-
cient HHT1 patients are associated with a loss of the capillary
network [11] ; second, mice lacking endoglin die at gestational
day 11.5, apparently from defective vascular development
[16] ; and third, augmented expression of endoglin has been
detected in endothelia from neovascularized tissues such as
tumors [20,25^28], Graves’ disease and Hashimoto’s thyroidi-
tis [29], psoriasis [30], scleroderma [31], or ischemic stroke
[20].
Fig. 4. Inhibition of TGF-L1 binding to endoglin in the presence of
anti-endoglin antibodies. Myoblasts overexpressing endoglin were
subjected to a⁄nity labeling with [125I]TGF-L1 in the presence of 5
or 50 Wg puri¢ed anti-endoglin or anti-TK3 immunoglobulins. Cells
were washed to remove unbound ligand and chemical cross-linking
with disuccinimidyl suberate was carried out. Cell extracts were sub-
jected to speci¢c immunoprecipitation with an anti-endoglin mAb.
Samples were subjected to SDS-PAGE under non-reducing condi-
tions. In the presence of 50 Wg of puri¢ed anti-endoglin immunoglo-
bulins the binding of [125I]TGF-L1 to endoglin is blocked. Bands
corresponding to oligomers, endoglin dimer, and putative receptors
I (RI) and II (RII) are indicated.
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TGF-L has been reported to be angiogenic or anti-angio-
genic in vivo, depending on the model system used [15]. In this
sense, our data indicate that addition of TGF-L1 to the chick
CAM has a potentiating angiogenic e¡ect, in agreement with
a previous report [32]. The molecular mechanism by which
antibodies to endoglin modulate in vivo angiogenesis is not
known. Since TGF-L1 shows an enhanced angiogenic e¡ect
similar to that of anti-endoglin, and the simultaneous addition
of TGF-L1 and anti-endoglin does not result in an additive
e¡ect, it is tempting to speculate that both are using the same
signaling pathway. We have shown that anti-endoglin anti-
bodies are able to interfere with TGF-L1 binding, suggesting
an epitope recognition at or near the endoglin ligand binding
site. Thus, one possibility is that anti-endoglin antibodies are
mimicking a ligand which leads to the release of endogenous
TGF-L1 or to a signaling pathway common to that of TGF-
L1. The facts that neovascularized tissues are associated with
high expression levels of endoglin and, conversely, a de¢cient
or null expression of endoglin is associated with a lack of
vascular development and remodeling support an active role
of endoglin in the angiogenic process. Whether the physiolog-
ical ligand of endoglin in this process is TGF-L1, TGF-L3,
activin, a yet unknown ligand [4^6], or a speci¢c combination
of them remains to be determined.
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